19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions : A Secondary Analysis of 2 Randomized Clinical Trials

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Psoriasis of the scalp, palms and/or soles, and nails is challenging to treat.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.

          The Nail Psoriasis Severity Index (NAPSI) is a numeric, reproducible, objective, simple tool for evaluation of nail psoriasis. This scale is used to evaluate the severity of nail bed psoriasis and nail matrix psoriasis by area of involvement in the nail unit. The NAPSI will be useful during clinical trials for evaluating response to treatment of psoriatic nails. The scale is reproducible, and because there are few data points, statistical analysis is simplified.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.

            Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

              Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P < .001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P < .001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P < .001). The study did not evaluate nail response beyond 1 year. Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement.
                Bookmark

                Author and article information

                Journal
                JAMA Dermatology
                JAMA Dermatol
                American Medical Association (AMA)
                2168-6068
                June 01 2018
                June 01 2018
                : 154
                : 6
                : 676
                Affiliations
                [1 ]Department of Medicine, The University of Melbourne, St Vincent’s Hospital, Melbourne, Victoria, Australia
                [2 ]Skin & Cancer Foundation Inc, Carlton, Victoria, Australia
                [3 ]Department of Dermatology, Medical College of Wisconsin, Milwaukee
                [4 ]Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, England
                [5 ]Janssen Research & Development, LLC, Spring House, Pennsylvania
                [6 ]Oregon Medical Research Center, Portland
                Article
                10.1001/jamadermatol.2018.0793
                711efb81-ff8e-4b7c-bdc6-9d5059a0beed
                © 2018
                History

                Comments

                Comment on this article